Latest Earnings Results: Q3 '26
Estimated EPS
-$0.71
Reported EPS
-$0.61
Surprise
+14.05%
Estimated Rev
$85.57M
Reported Rev
$92.13M
Surprise
+7.67%
• Reported GAAP EPS of -$0.61 up 25.61% YoY • Reported revenue of $92.13M up 79.59% YoY • For 2026, Rhythm Pharmaceuticals anticipates approximately $360M to $380M in Non-GAAP Operating Expenses, including R&D expenses of approximately $165M to $175M and SG&A expenses of approximately $195M to $205M.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$2.84 | -- | -- | N/A |
Q3 '26 | -$0.71 | -$0.61 | 14.05% | BEAT |
Q2 '26 | -$0.81 | -$0.73 | 9.56% | BEAT |
Q1 '26 | -$0.82 | -$0.83 | -0.61% | MISSED |
Q4 '25 | -$0.80 | -$0.73 | 9.26% | BEAT |